Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Pretreated Advanced Melanoma
NCT05370807Phase 2Active, not recruiting
- Sponsor
- UZ Brussel
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in melanoma, sponsored by UZ Brussel. Started Oct 2022; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05370807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370807.